Healthcare+ Expo 台灣醫療科技展
台灣醫療科技展 世延生醫分享今年重大進展
世延生醫 2025 年度重要進展亮眼 展現國際佈局成果
世延生醫今年於國際醫材法規方面成果豐碩：ELISA 檢測產品已取得澳洲、香港、越南、泰國及菲律賓的上市許可，快篩產品也成功取得新加坡核准。同時，團隊積極參與華南口腔展、越南 VIDEC、泰國 MEDICA 與德國 MEDICA，全面拓展海外市場。
臨床應用方面，林口長庚張凱評醫師於越南 SHNO-2025 第 9 屆亞洲頭頸部腫瘤學會年會發表世延生醫相關技術與產品；11 月亦於竹科精準健康跨域推升計畫成果發表會，展示公司以標靶定量質譜術開發的多標記胞泌體檢測套組。
本次展會亦感謝柳營奇美蔣維凡部長、竹科管理局游靜秋副局長及多位長官好友蒞臨指導，讓世延倍感鼓舞。
S&T BioMed Announces Major Achievements in 2025, Accelerating Its Global Expansion
S&T BioMed announced several key milestones this year. The company’s ELISA diagnostic product obtained medical device approvals in Australia, Hong Kong, Vietnam, Thailand, and the Philippines, while its rapid test received regulatory clearance in Singapore. To further expand its global footprint, S&T BioMed participated in major international exhibitions, including the South China Dental Show, Vietnam VIDEC, Thailand MEDICA, and Germany MEDICA.
On the clinical front, Dr. Kai-Ping Chang from Linkou Chang Gung Memorial Hospital presented S&T Biomed’s technology and products at SHNO-2025, the 9th Asian Society of Head and Neck Oncology Congress in Vietnam. In November, S&T BioMed also showcased its targeted quantitative mass spectrometry–based exosome assay (multi-marker panel) at the Hsinchu Science Park Precision Health Program Results Presentation.
The company was especially grateful for the support from distinguished guests, including Director Wei-Fan Chiang of Chi Mei Liouying and Deputy Director Ching-Chiu Yu of the Hsinchu Science Park Bureau, who visited during the exhibition.
